Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies
Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations
Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...